DMARD, disease modifying antirheumatic drug

Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis
G Haugeberg, M J Green, M A Quinn, H Marzo-Ortega, S Proudman, Z Karim, R J Wakefield, P G Conaghan, S Stewart, P Emery

Annals of the Rheumatic Diseases Jun 2006, 65 (6) 736-740; DOI: 10.1136/ard.2005.043869
Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?
Linda Mary Davies, Emily Anne Fargher, Karen Tricker, Peter Dawes, David L Scott, Deborah Symmons

Annals of the Rheumatic Diseases May 2007, 66 (5) 658-663; DOI: 10.1136/ard.2006.061234
Standardisation of synovial tissue infiltrate analysis: how far have we come? how much further do we need to go?
M D Smith, D Baeten, A-K Ulfgren, I B McInnes, O Fitzgerald, B Bresnihan, P P Tak, D Veale

Annals of the Rheumatic Diseases Jan 2006, 65 (1) 93-100; DOI: 10.1136/ard.2005.036905
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 889-894; DOI: 10.1136/ard.2005.043166
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment
P Durez, A Nzeusseu Toukap, B R Lauwerys, D H Manicourt, P Verschueren, R Westhovens, J-P Devogelaer, F A Houssiau

Annals of the Rheumatic Diseases Sep 2004, 63 (9) 1069-1074; DOI: 10.1136/ard.2003.012914
Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study
T Dervieux, D Furst, D O Lein, R Capps, K Smith, J Caldwell, J Kremer

Annals of the Rheumatic Diseases Aug 2005, 64 (8) 1180-1185; DOI: 10.1136/ard.2004.033399
Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients’ sickness absence and gross income: experience from the FIN-RACo trial
K Puolakka, H Kautiainen, M Pekurinen, T Möttönen, P Hannonen, M Korpela, M Hakala, M Arkela-Kautiainen, R Luukkainen, M Leirisalo-Repo

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 899-904; DOI: 10.1136/ard.2005.045807
Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis
J Wolf, T Stranzl, M Filipits, G Pohl, R Pirker, B Leeb, J S Smolen

Annals of the Rheumatic Diseases Apr 2005, 64 (4) 564-568; DOI: 10.1136/ard.2003.014985
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis
J C van Denderen, M van der Paardt, M T Nurmohamed, Y M M A de Ryck, B A C Dijkmans, I E van der Horst-Bruinsma

Annals of the Rheumatic Diseases Dec 2005, 64 (12) 1761-1764; DOI: 10.1136/ard.2005.036491
Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice
A A den Broeder, E de Jong, M J A M Franssen, M E C Jeurissen, M Flendrie, F H J van den Hoogen

Annals of the Rheumatic Diseases Jun 2006, 65 (6) 760-762; DOI: 10.1136/ard.2004.033662

Main menu

DMARD, disease modifying antirheumatic drug

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

DMARD, disease modifying antirheumatic drug

Pages